Literature DB >> 33526455

The Cell Biology of LRRK2 in Parkinson's Disease.

Ahsan Usmani1, Farbod Shavarebi1, Annie Hiniker2.   

Abstract

Point mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD) and are implicated in a significant proportion of apparently sporadic PD cases. Clinically, LRRK2-driven PD is indistinguishable from sporadic PD, making it an attractive genetic model for the much more common sporadic PD. In this review, we highlight recent advances in understanding LRRK2's subcellular functions using LRRK2-driven PD models, while also considering some of the limitations of these model systems. Recent developments of particular importance include new evidence of key LRRK2 functions in the endolysosomal system and LRRK2's regulation of and by Rab GTPases. Additionally, LRRK2's interaction with the cytoskeleton allowed elucidation of the LRRK2 structure and appears relevant to LRRK2 protein degradation and LRRK2 inhibitor therapies. We further discuss how LRRK2's interactions with other PD-driving genes, such as the VPS35, GBA1, and SNCA genes, may highlight cellular pathways more broadly disrupted in PD.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  LRRK2; Parkinson's disease; endolysosome; kinase; microtubule

Year:  2021        PMID: 33526455     DOI: 10.1128/MCB.00660-20

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  10 in total

Review 1.  LRRK2 and Proteostasis in Parkinson's Disease.

Authors:  María Dolores Pérez-Carrión; Inmaculada Posadas; Javier Solera; Valentín Ceña
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

2.  A guide to membrane atg8ylation and autophagy with reflections on immunity.

Authors:  Vojo Deretic; Michael Lazarou
Journal:  J Cell Biol       Date:  2022-06-14       Impact factor: 8.077

3.  Novel Macrocyclic LRRK2 Inhibitors for Treating Parkinson's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-01-03       Impact factor: 4.345

4.  Novel N-Heteroaryl Quinazolin-2-amine Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-06-09       Impact factor: 4.632

5.  Targeted disruption of GAK stagnates autophagic flux by disturbing lysosomal dynamics.

Authors:  Masaya Miyazaki; Masaki Hiramoto; Naoharu Takano; Hiroko Kokuba; Jun Takemura; Mayumi Tokuhisa; Hirotsugu Hino; Hiromi Kazama; Keisuke Miyazawa
Journal:  Int J Mol Med       Date:  2021-09-01       Impact factor: 4.101

Review 6.  Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies.

Authors:  Kenya Nishioka; Yuzuru Imai; Hiroyo Yoshino; Yuanzhe Li; Manabu Funayama; Nobutaka Hattori
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

Review 7.  Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.

Authors:  Jacob Helm; Ludger Schöls; Stefan Hauser
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525

Review 8.  Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.

Authors:  Gunjan Thakur; Vikas Kumar; Keun Woo Lee; Chungkil Won
Journal:  Genes (Basel)       Date:  2022-08-11       Impact factor: 4.141

9.  Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.

Authors:  Alexia F Kalogeropulou; Elena Purlyte; Francesca Tonelli; Sven M Lange; Melanie Wightman; Alan R Prescott; Shalini Padmanabhan; Esther Sammler; Dario R Alessi
Journal:  Biochem J       Date:  2022-09-16       Impact factor: 3.766

Review 10.  Retromer dependent changes in cellular homeostasis and Parkinson's disease.

Authors:  Zhe Yang; Zebin Li; Rohan D Teasdale
Journal:  Essays Biochem       Date:  2021-12-22       Impact factor: 8.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.